文章基本信息

标题：Clinical profile and initial treatment of non-small cell lung cancer: a retrospective cohort study at the Uganda Cancer Institute
本地全文：下载
作者：Solomon Kibudde ; Solomon Kibudde ; Bruce James Kirenga 等
期刊名称：African Health Sciences
印刷版ISSN：1680-6905
电子版ISSN：1729-0503
出版年度：2021
卷号：21
期号：4
页码：1739-1745
DOI：10.4314/ahs.v21i4.30
语种：English
出版社：Makerere University Medical School（Uganda)
摘要：Introduction Lung cancer is a major global public health burden constituting 11.6% of all new cancer diagnoses and 18.4% of all cancer-related mortality Purpose To describe the clinical profile and initial treatment of non-small cell lung cancer in Uganda Methods We reviewed charts of a cohort of patients with a histologically confirmed diagnosis of non-small cell lung cancer, treated between January 2013 and November 2015 at the Uganda Cancer Institute. Results A total of 74 patients met the inclusion criteria. The median age was 56 years (IQR 47–70), with 16.2% below the age 45 years, and 51% were female. Only 10 percent were active smokers and the most frequent histological subtype was adenocarcinoma (71%). The majority (91.9%) had stage IV disease at diagnosis and frequent metastases to contralateral lung, liver, and bones. Twenty-seven (27) patients received platinum-based chemotherapy, while 27 patients received erlotinib, and only 4 patients received palliative thoracic radiotherapy. The median survival time was 12.4 months, and the overall response rate was 32.7%. There was no survival difference by type of systemic treatment, and on multivariate analysis, poor performance status was predictive of adverse outcomes (p < 0.001). Conclusions Patients with non-small cell lung cancer in Uganda frequently presented with late-stage disease at diagnosis. The majority of patients were female, never-smokers, and had predominantly adenocarcinoma subtype.
关键词：Non-small cell lung cancer;Uganda;erlotinib;lung cancer;Uganda Cancer Institute